As the Australian market follows the global uptick, with ASX 200 futures indicating a positive start, investors are keenly observing opportunities that arise from this buoyant sentiment. Penny stocks, though an older term, still capture interest due to their potential for growth and value in smaller or newer companies. In this context, we explore three noteworthy penny stocks on the ASX that stand out for their financial robustness and potential to offer significant returns over time.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Rewards & Risks |
| Alfabs Australia (ASX:AAL) | A$0.505 | A$144.73M | ✅ 4 ⚠️ 3 View Analysis > |
| EZZ Life Science Holdings (ASX:EZZ) | A$2.18 | A$102.84M | ✅ 3 ⚠️ 2 View Analysis > |
| Dusk Group (ASX:DSK) | A$0.82 | A$51.06M | ✅ 4 ⚠️ 2 View Analysis > |
| IVE Group (ASX:IGL) | A$2.69 | A$415.94M | ✅ 4 ⚠️ 3 View Analysis > |
| MotorCycle Holdings (ASX:MTO) | A$3.41 | A$251.68M | ✅ 4 ⚠️ 2 View Analysis > |
| Pureprofile (ASX:PPL) | A$0.043 | A$50.3M | ✅ 3 ⚠️ 1 View Analysis > |
| West African Resources (ASX:WAF) | A$3.04 | A$3.47B | ✅ 4 ⚠️ 1 View Analysis > |
| Praemium (ASX:PPS) | A$0.79 | A$377.39M | ✅ 5 ⚠️ 2 View Analysis > |
| Service Stream (ASX:SSM) | A$2.34 | A$1.43B | ✅ 3 ⚠️ 1 View Analysis > |
| Fleetwood (ASX:FWD) | A$3.00 | A$277M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 430 stocks from our ASX Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Alcidion Group (ASX:ALC)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Alcidion Group Limited develops and licenses healthcare software products in Australia, New Zealand, and the United Kingdom, with a market cap of A$134.30 million.
Operations: The company generates revenue primarily from the provision of healthcare software solutions, amounting to A$40.79 million.
Market Cap: A$134.3M
Alcidion Group Limited, with a market cap of A$134.30 million, has shown promising financial improvements recently. The company reported A$40.79 million in sales for the year ending June 2025, up from A$37.06 million the previous year, and turned a net income of A$1.65 million compared to a net loss last year. This marks its transition to profitability after five years of losses, although its Return on Equity remains low at 1.9%. Alcidion is debt-free and maintains stable weekly volatility at 9%, suggesting some financial stability despite large one-off items impacting earnings quality.
- Jump into the full analysis health report here for a deeper understanding of Alcidion Group.
- Review our growth performance report to gain insights into Alcidion Group's future.
Accent Group (ASX:AX1)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand with a market cap of A$817.61 million.
Operations: The company generates revenue primarily from its retail segment, which accounts for A$1.30 billion, and its wholesale segment, contributing A$459.71 million.
Market Cap: A$817.61M
Accent Group, with a market cap of A$817.61 million, has been actively enhancing its retail operations through strategic alliances, such as expanding its partnership with Bamboo Rose for improved merchandise planning using AI-driven insights. Although the company's earnings growth has been modest at 1.3% annually over five years, it remains financially stable with operating cash flow well covering debt and short-term assets exceeding liabilities. Despite facing a decline in net profit margins from 4.1% to 3.9%, Accent is trading at good value compared to peers and maintains satisfactory debt levels with interest payments well covered by EBIT.
- Navigate through the intricacies of Accent Group with our comprehensive balance sheet health report here.
- Assess Accent Group's future earnings estimates with our detailed growth reports.
Cyclopharm (ASX:CYC)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Cyclopharm Limited manufactures and sells medical equipment and radiopharmaceuticals globally, with a market cap of A$97.80 million.
Operations: The company generates revenue from its Medical Imaging Systems segment, totaling A$30.72 million.
Market Cap: A$97.8M
Cyclopharm Limited, with a market cap of A$97.80 million, reported H1 2025 revenue of A$15.42 million, up from A$12.27 million year-on-year, yet remains unprofitable with a net loss of A$7.69 million. The company is debt-free and covers its liabilities effectively with short-term assets totaling A$36.3M against liabilities of A$19.9M combined long and short term. Despite being unprofitable and having less than one year of cash runway, Cyclopharm's revenue is expected to grow significantly at 36% annually per forecasts, although profitability isn't anticipated within the next three years.
- Take a closer look at Cyclopharm's potential here in our financial health report.
- Understand Cyclopharm's earnings outlook by examining our growth report.
Summing It All Up
- Navigate through the entire inventory of 430 ASX Penny Stocks here.
- Contemplating Other Strategies? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Cyclopharm might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com